Valeant was once considered a runaway success story, and one that upended the pharmaceutical sector. A series of crises engulfed the company in recent months, slashing nearly two thirds off its market valuation and forcing the company to tear up its forecasts for 2016. Correspondent David Crow explains. Read the full story at ft.com/valeant. Music: "Brand New Record!" by Steve Combs

View our accessibility guide.

Copyright The Financial Times Limited 2024. All rights reserved.
Reuse this content (opens in new window) CommentsJump to comments section

Follow the topics in this audio

Comments

Comments have not been enabled for this article.